A cell therapy approach based on transplanting a type of lung cells called type II alveolar cells halted scarring (fibrosis) in a rat model of idiopathic pulmonary fibrosis (IPF) with established disease. This anti-fibrotic effect was associated with a drop in lung levels of several fibrotic markers, the researchers said.
News
Treating acute exacerbations with the protein thrombomodulin (ART-123) in idiopathic pulmonary fibrosis (IPF) patients may be associated with short-term survival benefits, a review analysis reports. However, larger studies are needed to confirm these findings, the researchers noted. The study, “Efficacy…
New preclinical data support MRG-229, an investigative next-generation treatment for idiopathic pulmonary fibrosis (IPF), as safe and effective, miRagen reported. “We believe this body of evidence supports further development of MRG-229 as a potentially differentiated approach for the treatment of IPF,” William S. Marshall, PhD, the company’s president and CEO, said in…
Former New York Yankees center fielder and Latin Grammy nominee Bernie Williams is helping to raise awareness of idiopathic pulmonary fibrosis (IPF), the disease took his father’s life, as part of Boehringer Ingelheim’s national Breathless Ballad Challenge. The campaign aims to educate and empower people who have, or suspect…
Pulmonary fibrosis (PF) that results from inhaling silica dust is rebounding in wealthier counties after years of decline, due to a  rising demand for artificial stone in home construction and renovation, a study from Spain reports. The study traces the disease in a group of people who worked with…
Low levels of a protein called esRAGE, present in the blood and lungs of people with idiopathic pulmonary fibrosis (IPF), are associated with a poorer prognosis and lower survival rates, a study shows. These findings suggest that esRAGE may be related…
The Alexion Charitable Foundation has awarded $1.1 million in grants to programs that support those with rare diseases during the COVID-19 pandemic, the organization recently announced. The grants will support activities that align with the foundation’s Rare Belonging focus, a set of funding priorities aimed at improving the…
How idiopathic pulmonary fibrosis (IPF) patients assess their own symptoms and physical capacity predicts, to some degree, their risk of dying or of needing a lung transplant, according to a recent study. The study, “Associations Between Patient-Reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary…
Veracyte’s Envisia Genomic Classifier, the first commercially available genomic test to help diagnose idiopathic pulmonary fibrosis (IPF), can help physicians identify the disease in patients where other tests have been inconclusive, according to real-world data from a recent study. The study, “Employing Bronchoscopic Lung…
Galapagos and e-therapeutics are partnering to investigate mechanisms involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions and to select potential therapeutic candidates. The collaboration will combine Galapagos’ extensive knowledge on IPF and fibrosis with e-therapeutics’ Network-driven Drug Discovery (NDD) platform for examining disease mechanisms…
